These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34791318)

  • 1. Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.
    Jacobs TG; Marzolini C; Back DJ; Burger DM
    J Antimicrob Chemother; 2022 Feb; 77(3):568-573. PubMed ID: 34791318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.
    Stader F; Kinvig H; Battegay M; Khoo S; Owen A; Siccardi M; Marzolini C
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
    Ohno Y; Hisaka A; Ueno M; Suzuki H
    Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
    Iga K; Kiriyama A
    J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
    Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R
    Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
    Zhou SF
    Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID?
    Smythe MA; Burns C; Liu Q; Garwood CL
    Ann Pharmacother; 2022 Mar; 56(3):319-329. PubMed ID: 34137279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
    Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
    Yu J; Wang Y; Ragueneau-Majlessi I
    Clin Ther; 2022 Nov; 44(11):1536-1544. PubMed ID: 36210218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
    Courlet P; Guidi M; Alves Saldanha S; Cavassini M; Stoeckle M; Buclin T; Marzolini C; Decosterd LA; Csajka C
    Eur J Clin Pharmacol; 2021 Jul; 77(7):979-987. PubMed ID: 33452585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition.
    Di Paolo V; Ferrari FM; Poggesi I; Quintieri L
    Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1345-1352. PubMed ID: 34720033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction.
    Le Corvaisier C; Capelle A; France M; Bourguignon L; Tod M; Goutelle S
    Fundam Clin Pharmacol; 2021 Apr; 35(2):208-216. PubMed ID: 32813881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087).
    Haigentz M; Lee JY; Chiao EY; Aboulafia DM; Ratner L; Ambinder RF; Baiocchi RA; Mitsuyasu RT; Wachsman W; Sparano JA; Rudek MA
    Clin Cancer Res; 2023 Dec; 29(24):5038-5046. PubMed ID: 37523145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
    Lakatos B; Kowalska J; Antoniak S; Gokengin D; Begovac J; Vassilenko A; Wasilewski P; Fleischhans L; Jilich D; Matulionyte R; Kase K; Papadopoulus A; Rukhadze N; Harxhi A; Hofman S; Dragovic G; Vasyliev M; Verhaz A; Yancheva N; Oprea C;
    HIV Med; 2022 Jul; 23(6):693-700. PubMed ID: 34859557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa.
    Strope JD; Lochrin SE; Sissung TM; Kem R; Chandrasekaran P; Sharon E; Price DK; Uldrick TS; Yarchoan R; Figg WD
    AIDS Rev; 2020 Oct; 23(1):13-27. PubMed ID: 33105469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
    Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
    Li A; Yeo K; Welty D; Rong H
    Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
    Waters NJ
    Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.